Literature DB >> 29380188

Comparative Study of the Effects of Fluconazole and Voriconazole on Candida glabrata, Candida parapsilosis and Candida rugosa Biofilms.

Priya Madhavan1,2, Farida Jamal3, Chong Pei Pei4, Fauziah Othman5, Arunkumar Karunanidhi3,6, Kee Peng Ng7.   

Abstract

Infections by non-albicans Candida species are a life-threatening condition, and formation of biofilms can lead to treatment failure in a clinical setting. This study was aimed to demonstrate the in vitro antibiofilm activity of fluconazole (FLU) and voriconazole (VOR) against C. glabrata, C. parapsilosis and C. rugosa with diverse antifungal susceptibilities to FLU and VOR. The antibiofilm activities of FLU and VOR in the form of suspension as well as pre-coatings were assessed by XTT [2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide] reduction assay. Morphological and intracellular changes exerted by the antifungal drugs on Candida cells were examined by scanning electron microscope (SEM) and transmission electron microscope (TEM). The results of the antibiofilm activities showed that FLU drug suspension was capable of killing C. parapsilosis and C. rugosa at minimum inhibitory concentrations (MICs) of 4× MIC FLU and 256× MIC FLU, respectively. While VOR MICs ranging from 2× to 32× were capable of killing the biofilms of all Candida spp tested. The antibiofilm activities of pre-coated FLU were able to kill the biofilms at ¼× MIC FLU and ½× MIC FLU for C. parapsilosis and C. rugosa strains, respectively. While pre-coated VOR was able to kill the biofilms, all three Candida sp at ½× MIC VOR. SEM and TEM examinations showed that FLU and VOR treatments exerted significant impact on Candida cell with various degrees of morphological changes. In conclusion, a fourfold reduction in MIC50 of FLU and VOR towards ATCC strains of C. glabrata, C. rugosa and C. rugosa clinical strain was observed in this study.

Entities:  

Keywords:  Biofilms; Electron microscopy; Fluconazole; Non-albicans Candida; Voriconazole; XTT assay

Mesh:

Substances:

Year:  2018        PMID: 29380188     DOI: 10.1007/s11046-018-0243-z

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  55 in total

1.  Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis isolated from patients with candidemia.

Authors:  Emilia Cantón; Javier Pemán; Guillermo Quindós; Elena Eraso; Ilargi Miranda-Zapico; María Álvarez; Paloma Merino; Isolina Campos-Herrero; Francesc Marco; Elia Gomez G de la Pedrosa; Genoveva Yagüe; Remedios Guna; Carmen Rubio; Consuelo Miranda; Carmen Pazos; David Velasco
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

Review 2.  Candida biofilms: antifungal resistance and emerging therapeutic options.

Authors:  Duncan M Kuhn; Mahmoud A Ghannoum
Journal:  Curr Opin Investig Drugs       Date:  2004-02

3.  Phenotype switching affects biofilm formation by Candida parapsilosis.

Authors:  Sean F Laffey; Geraldine Butler
Journal:  Microbiology       Date:  2005-04       Impact factor: 2.777

4.  Cloning and characterization of a complex DNA fingerprinting probe for Candida parapsilosis.

Authors:  L Enger; S Joly; C Pujol; P Simonson; M Pfaller; D R Soll
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

5.  A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei.

Authors:  H Sanati; P Belanger; R Fratti; M Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

6.  Identification of local clinical Candida isolates using CHROMagar Candida™ as a primary identification method for various Candida species.

Authors:  P Madhavan; F Jamal; P P Chong; K P Ng
Journal:  Trop Biomed       Date:  2011-08       Impact factor: 0.623

7.  Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance.

Authors:  J Chandra; D M Kuhn; P K Mukherjee; L L Hoyer; T McCormick; M A Ghannoum
Journal:  J Bacteriol       Date:  2001-09       Impact factor: 3.490

Review 8.  Antifungal lock therapy.

Authors:  Carla J Walraven; Samuel A Lee
Journal:  Antimicrob Agents Chemother       Date:  2012-10-15       Impact factor: 5.191

9.  Stimulation of the autophagic activity in blastospores of Candida albicans exposed in vitro to fluconazole.

Authors:  S Pancaldi; G Dall'Olio; F Poli; M P Fasulo
Journal:  Microbios       Date:  1994

10.  Genetic relatedness of commensal strains of Candida albicans carried in the oral cavity of patients' dental prosthesis users in Brazil.

Authors:  Regina Helena Pires-Gonçalves; Elaine Toscano Miranda; Lilian Cristiane Baeza; Marcelo Teruyuki Matsumoto; José Eduardo Zaia; Maria José Soares Mendes-Giannini
Journal:  Mycopathologia       Date:  2007-09-29       Impact factor: 2.574

View more
  3 in total

Review 1.  Emerging Roles of Functional Bacterial Amyloids in Gene Regulation, Toxicity, and Immunomodulation.

Authors:  Nir Salinas; Tatyana L Povolotsky; Meytal Landau; Ilana Kolodkin-Gal
Journal:  Microbiol Mol Biol Rev       Date:  2020-11-25       Impact factor: 11.056

2.  Copper(II) and Zinc(II) Complexes with the Clinically Used Fluconazole: Comparison of Antifungal Activity and Therapeutic Potential.

Authors:  Nevena Lj Stevanović; Ivana Aleksic; Jakob Kljun; Sanja Skaro Bogojevic; Aleksandar Veselinovic; Jasmina Nikodinovic-Runic; Iztok Turel; Miloš I Djuran; Biljana Đ Glišić
Journal:  Pharmaceuticals (Basel)       Date:  2020-12-30

3.  Fluconazole and Lipopeptide Surfactin Interplay During Candida albicans Plasma Membrane and Cell Wall Remodeling Increases Fungal Immune System Exposure.

Authors:  Jakub Suchodolski; Daria Derkacz; Jakub Muraszko; Jarosław J Panek; Aneta Jezierska; Marcin Łukaszewicz; Anna Krasowska
Journal:  Pharmaceutics       Date:  2020-04-01       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.